anchor.diff:  
                  1. INR > 1.5
   
  -               2. Platelets < 50 Ã— 109/L (Note that platelets are required to be â‰¥100Ã— 109/L at
  +               2. Platelets < 50  109/L (Note that platelets are required to be 100 109/L at
                     screening)
   
                  3. Therapeutic anticoagulant treatment that can't be held for 24 hours. Low dose
  
positive.code:                   progression)
  
           11. Females of childbearing potential must have a negative beta human chorionic
               gonadotropin (Î²-hCG) pregnancy test result within 7 days prior to the first dose of
               study drug. Females of non-childbearing potential are those who are postmenopausal
               greater than 1 year or who have had a bilateral tubal ligation or hysterectomy.
  
  
negative.code:           -  Subject has received potent CYP 3A4 inhibitors within 7 days prior to first dose of
               study drug or proton pump inhibitors such as omeprazole within 14 days prior to first
               dose of study drug.
        "
  NCT02395172,Phase 3,"EMD Serono Research & Development Institute, Inc.",Industry,"A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Docetaxel in Subjects With Non-small Cell Lung Cancer That Has Progressed After a Platinum-containing Doublet",1,18,150,include,include,,,,,include,include,,,,,,exclude,exclude,,,,require,,,,,,"
          Inclusion Criteria
  
  